About the Authors
- Estrella Lasry-Levy, Diana N. J. Lockwood
- London School of Hygiene & Tropical Medicine, London, United Kingdom
- Aki Hietaharju
- Department of Neurology, Tampere University Hospital, Tampere, Finland
- Vivek Pai, Ramaswamy Ganapati
- Bombay Leprosy Project, Sion Chunabhatti, Mumbai, India
- Andrew S. C. Rice
- Department of Anaesthetics, Pain Medicine & Intensive Care, Faculty of Medicine, Imperial College, London, United Kingdom
- Maija Haanpää
- Department of Neurosurgery, Helsinki University Hospital, Helsinki, Finland
- Maija Haanpää
- ORTON Rehabilitation, Helsinki, Finland
In the last 12 months Aki Hietaharju has been a member of Pfizer Medical Advisory Board (one meeting). In the last 12 months Aki Hietaharju has received consultancy fees and expenses from Pfizer, Orion, Bayer Schering, Octapharma, Boehringer Ingelheim, Baxter, Shire, UCB Pharma and Roche. In the last 12 months Andrew Rice has received consultancy fees and expenses contracted via Imperial College Consultants from: Pfizer, Eisai, Spinifex, Astellas, Allergan, NeuroGsx, Daiichi Sankyo and GlaxoSmithKline. In the last 12 months Andrew Rice has received research funding from Pfizer and Spinifex. Andrew Rice is a member of the EU research collaboration Innovative Medicines Initiative “Europain”. Industry partners in this grant are: Pfizer, Esteve, GlaxoSmithKline, Astra Zeneca, Boehringer Ingelheim, UCB Pharma, Wyeth, Eli Lilly and Sanofi-Aventis.
Conceived and designed the experiments: ELL AH DNJL. Performed the experiments: ELL VP RG. Analyzed the data: ELL. Wrote the paper: ELL AH VP RG ASCR MH DNJL. Provided neuropathic pain expertise and counselling: AH ASCR MH.